Expression of interleukin‐17 is correlated with interferon‐α expression in cutaneous lesions of lupus erythematosus

@article{Oh2011ExpressionOI,
  title={Expression of interleukin‐17 is correlated with interferon‐$\alpha$ expression in cutaneous lesions of lupus erythematosus},
  author={S. H. Oh and Hyun-Jin Roh and Ji Eun Kwon and Sang Han Lee and Ja Yeon Kim and H J Choi and B J Lim},
  journal={Clinical and Experimental Dermatology},
  year={2011},
  volume={36}
}
  • S. Oh, H. Roh, +4 authors B. J. Lim
  • Published 1 July 2011
  • Medicine
  • Clinical and Experimental Dermatology
Background.  Type I interferon (IFN) has been reported to have an important role in the development of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). A new subset of CD4+ T cells, T helper (Th)17 cells, also plays a role in the development of autoimmunity. 
The pathogenesis of cutaneous lupus erythematosus: The aberrant distribution and function of different cell types in skin lesions
TLDR
The aberrant distribution and function of different cells types involved in this disease are discussed and will offer a new direction for research and therapy in the near future.
Interleukin-17 and lupus: enough to be a target? For which patients?
TLDR
The identification of subsets of SLE patients with an IL-17-driven disease now constitutes the key priority before starting trials, and more preclinical studies are needed to improve the selection of the right patients able to respond and tolerate the many inhibitors that are already available.
Characterization of autoantibodies and cytokines related to cutaneous lupus erythematosus
TLDR
Serum anti-RPLP0, anti-galectin3 antibodies, IFN-α, IFn-λ1 and IL-17A/F are associated with the occurrence of lupus skin lesions regardless of the systemic complications, whereas the profiles of these inflammatory mediators vary with the subtypes of l upus skin injuries.
Cytokines in Lupus
Abstract The broad activation of the interferon (IFN)-I pathway in cells of patients with lupus, along with rapid progress in the elucidation of the toll-like receptor system, has helped reformulate
The mechanism of skin damage
TLDR
The clinical aspects associated with skin damage are focused on and the underlying cellular and cytokine networks that result in skin damage in LE are illustrated.
Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus.
TLDR
Establishing a current picture of the IL-17 pre-clinical situation in SLE is timely in order to plan future proof-of-concept studies in human.
Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies
TLDR
This review will highlight the current understanding of CLE immunopathogenesis, the ongoing clinical trial landscape, and provide a framework for designing future therapeutic strategies for CLE based on new insights into disease pathogenesis.
Myxovirus Resistance Protein A Is a Useful Additional Histological Marker in Suspected Cutaneous Lupus Erythematosus.
TLDR
Cutaneous lupus erythematosus (CLE) is a heterogeneous autoimmune skin disease and IFN-related markers, such as myxovirus resistance protein A (MxA), could be helpful in the diagnostic process.
Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review.
TLDR
Cutaneous lupus erythematosus (CLE) refers to those subtypes of lupi that have predominantly skin manifestations and Cellular and cytokine networks can be impacted by environmental factors and genetic variations and this can result in an increased risk of developing autoimmune diseases such as CLE.
Cytokines and Effector/Regulatory Cells Characterization in the Physiopathology of Cutaneous Lupus Erythematous: A Cross-Sectional Study
TLDR
A proinflammatory and regulatory imbalance coexists in cutaneous lupus, both responses being more intense in DLE.
...
1
2
3
4
...

References

SHOWING 1-10 OF 65 REFERENCES
Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus
TLDR
It is suggested that a complex network of IFN-associated cytokines, chemokines and adhesion molecules orchestrates and promotes tissue injury observed in LE skin.
The expression of human leukocyte antigen‐DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity
TLDR
This work investigated whether the expression of activation markers on circulating T cells reflects disease activity in patients with SLE and whether this also holds true for patients with CLE.
The expression pattern of interferon‐inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets
TLDR
It is hypothesized that the expression pattern of IFN‐inducible proteins reflects the characteristic distribution of the inflammatory infiltrate in different subsets of cutaneous LE.
Identification of type I interferon‐associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches
TLDR
The role of type I IFNs, adhesion molecules and chemokine receptors in CLE are reviewed and options for novel therapeutic approaches are discussed.
Enhanced type I interferon signalling promotes Th1‐biased inflammation in cutaneous lupus erythematosus
TLDR
Expression of IP10/CXCL10 in the epidermis links type I IFN signalling and recruitment of CXCR3+ T cells in the skin, suggesting an important role for type I interferon signalling in the pathogenesis of cutaneous lupus erythematosus.
Lupus‐like reaction to interferon at the injection site: report of five cases
TLDR
To the authors' knowledge, a microscopic self‐resolving lesion mimicking lupus erythematosus at the injection site of interferon has not been described.
IL-17 and the Th17 lineage in systemic lupus erythematosus
TLDR
This review focuses on an emerging role for the cytokine IL-17 and the cells that produce it in contributing to lupus in particular based on recent findings in animal models.
Rationale for interleukin-6 blockade in systemic lupus erythematosus
TLDR
It is proposed that blocking the effect of IL-6 in humans may improve lupus by interacting with the autoinflammatory process both systemically and locally.
Interleukin-17 in inflammatory skin disorders
TLDR
Whereas IL-17 may play an important role in the pathogenesis of psoriasis and contact hypersensitivity, its role in atopic dermatitis is still unclear.
Type-I interferons and systemic lupus erythematosus.
TLDR
Several systemic clinical symptoms and laboratory findings can indeed be interpreted as downstream effects of a high IFNalpha production, and point to this cytokine as a link between the expansion of autoimmune B-cells and the stimulation of other components of the immune system.
...
1
2
3
4
5
...